Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 63M | 94M | 46M | 38M | 87M |
| Gross Profit | 56M | 94M | 39M | 31M | 79M |
| Operating Income | 55M | 101M | 45M | -61M | 86M |
| EBITDA | 55M | 101M | 45M | -60M | 87M |
| Net Income | 55M | 93M | 38M | -63M | 85M |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$12.69
+2.42% today
1Y Change
+20.71%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abrdn World Healthcare Fund (THW) is a fund with a market cap of $510.00M and listed on NYSE. The fund last traded around $12.69 and up 20.7% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include a dividend yield of 11.1%. Valuation already assumes a fairly strong business story at P/E 8.8 and price/sales 79.8. Stock Foundry combines THW price history, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
THW Max Drawdown
-14.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for THW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$86.5M
+127.1% YoY
FY Net Income
$85.1M
+235.5% YoY
Free Cash Flow
-$55.3M
-214.2% YoY
Revenue Growth
-33.2%
EPS Growth
-41.4%
Gross Margin
-119.7%
Net Margin
871.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 63M | 94M | 46M | 38M | 87M |
| Gross Profit | 56M | 94M | 39M | 31M | 79M |
| Operating Income | 55M | 101M | 45M | -61M | 86M |
| EBITDA | 55M | 101M | 45M | -60M | 87M |
| Net Income | 55M | 93M | 38M | -63M | 85M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 488K | 246 | 2K | 985 | 293 |
| Total Assets | 637M | 614M | 570M | 583M | 714M |
| Total Liabilities | 124M | 123M | 123M | 129M | 148M |
| Shareholder Equity | 513M | 491M | 447M | 454M | 566M |
| Total Debt | 121M | 120M | 120M | 120M | 120M |
| Net Debt | 121M | -246 | 120M | 120M | 120M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
55M
-214.2% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
55M
-214.2% YoY
Key ratios
Gross Margin
-119.7%
Operating Margin
980.1%
Net Margin
871.1%
ROE
11.6%
Debt / Equity
0.24x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.